Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19226278 | 0.96 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL23771912 | 0.96 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL20729403 | 0.96 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL19302676 | 0.96 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL28275409 | 0.91 | CYP19A1 (0.34) | CYP19A1OPRM1TLR8TBXAS1 | |
| SCHEMBL11867610 | 0.83 | CYP19A1 (0.36) | CYP19A1OPRM1TLR8 | |
| Bromide SCHEMBL29191437 | 0.82 | OPRM1 (0.36) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL11194903 | 0.81 | OPRM1 (0.39) | CYP19A1OPRM1TLR8TBXAS1 | |
| SCHEMBL20397465 | 0.80 | CYP19A1 (0.34) | CYP19A1OPRM1TLR8TBXAS1 | |
| SCHEMBL24862793 | 0.79 | CYP19A1 (0.36) | CYP19A1OPRM1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | GIFU UNIVERSITY (JP) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094017-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM | APOB, TTPA, AOX1 | CYP19A1 2665/4885OPRM1 4155/4885TLR8 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.